-
-
-
-
-
-
-
Arcus Biosciences (RCUS) Misses Q1 EPS by 12c
-
-
-
-
-
-
-
Arcus Biosciences (RCUS) Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10
-
-
-
-
-
-
-
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
-
-
-
-
-
-
-
Gilead Sciences (GILD), Arcus (RCUS) Announce Amended Collaboration and $320M Equity Investment
-
-
-
-
-
-
-
Arcus Biosciences (RCUS) Tops Q2 EPS by 6c
-
-
-
-
-
-
-
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides a Pipeline Update
-
-
-
-
-
-
-
Arcus Biosciences Reports Third Quarter 2022 Financial Results and Provides a Pipeline Update
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

